Reviewer's report

Title: A puzzling rash associated with hydralazine-induced ANCA-positive renal vasculitis.

Version: 1 Date: 18 October 2012

Reviewer: Mirela Dobre

Which of the following best describes what type of case report this is?: Unreported or unusual side effects or adverse interactions involving medications

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: Yes

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: Yes

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

Keasberry et al. describe an interesting case of Hydralazine induced ANCA vasculitis presenting with a rash. The case is well written and concise.

Major Comments:
1. It will greatly increase the quality of the paper if the authors will conduct a literature review of other few cases of Hydralazine induced ANCA+ pauci-immune glomerulonephritis that presented with a rash.

Minor comments:
1. Mane and nocte are not standard abbreviations and would spell out their meaning.
2. It would be important to specify the time interval when the repeat blood / urine tests were done.

3. What was patient baseline creatinine? This would be important to know on a patient with resistant hypertension, and factor V mutation.

4. Would include measurements units for all urinary and blood markers mentioned in the text.

5. How long was the duration of treatment and the dose for mycophenolate mofetil and prednisolone?

4. On page 5 the reference to Figure 2 is made in a phrase that discuss about the skin rash, when in fact Figure 2 is a microscopic image of the skin biopsy. It would be good to include in the discussion about skin findings, the differences between this case and Sweet Syndrome.

**Quality of written English:** Acceptable

**Declaration of competing interests:**

No competing interests